Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | PRESIDENT AND COO | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Gift · Disposed 11,728 · Balance 0 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Indirectby Trust | 99,720 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Gift · Acquired 11,728 · Balance 99,720 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2021 Filed Aug 18, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,000 | $53.83 | $215,320.00 |
DisclosureSEC source: 0001127602-21-023981 · form4.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 4,000 | $0.00 Strike: $53.83 | $0.00 |
DisclosureSEC source: 0001127602-21-023709 · form4.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 4,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 4,000 | $203.05 | $812,200.00 |
DisclosureSEC source: 0001127602-21-023709 · form4.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 12:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,000 | $53.83 | $215,320.00 |
DisclosureSEC source: 0001127602-21-023709 · form4.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 4,000 | $0.00 Strike: $53.83 | $0.00 |
DisclosureSEC source: 0001127602-21-023528 · form4.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 4,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 4,000 | $204.34 | $817,360.00 |
DisclosureSEC source: 0001127602-21-023528 · form4.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,000 | $53.83 | $215,320.00 |
DisclosureSEC source: 0001127602-21-023528 · form4.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 4,000 | $0.00 Strike: $53.83 | $0.00 |
DisclosureSEC source: 0001127602-21-023278 · form4.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 4,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 4,000 | $205.42 | $821,680.00 |
DisclosureSEC source: 0001127602-21-023278 · form4.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,000 | $53.83 | $215,320.00 |
DisclosureSEC source: 0001127602-21-023278 · form4.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 6,450 | $0.00 Strike: $47.50 | $0.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,450 shares Expires 2022-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 21,750 | $0.00 Strike: $68.14 | $0.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · derivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,750 shares Expires 2021-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 6,450 | $133.98 | $864,171.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,998 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,450 | $47.50 | $306,375.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 21,750 | $133.98 | $2,914,065.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,998 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:43 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 21,750 | $68.14 | $1,482,045.00 |
DisclosureSEC source: 0001127602-20-028031 · form4.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:26 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 187,500 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001127602-19-011991 · form4.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2027-03-15 F2 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F5 · derivative.exercise_date: These stock options will vest in equal one-third installments on March 15, 2021, 2022 and 2023. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 12:26 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 187,500 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001127602-19-011991 · form4.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2027-03-15 F2 · security: These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. F3 · derivative.exercise_price: Exercise price is equal to 115% of the closing price for the Company's common stock on the date of grant. F4 · derivative.exercise_date: This award will cliff vest (100%) on March 15, 2023. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 22:49 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 64,148 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008759 · form4.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,148 Underlying: Common Stock · 64,148 shares Expires 2028-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a one-year performance condition tied to company-wide milestone performance for 2018, which was determined on February 27, 2019. Number of stock options reported represents the number of options earned based on milestone performance. F3 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2019, 2020 and 2021. Read SEC document |
| March 15, 2018 Filed Mar 16, 2021 22:50 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 85,531 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010883 · form4a.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,531 Underlying: Common Stock · 85,531 shares Expires 2028-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profit margin during 2018-2020, which was determined on February 24, 2021. Number of stock options reported represents the number of options earned based on performance. F3 · derivative.expiration_date: This Form 4/A is being filed to correct the expiration date of this award. Read SEC document |
| March 15, 2018 Filed Mar 16, 2021 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 85,531 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010809 · form4.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,531 Underlying: Common Stock · 85,531 shares Expires 2018-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profit margin during 2018-2020, which was determined on February 24, 2021. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
| February 21, 2018 Filed Feb 26, 2018 21:11 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 42,940 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-18-008402 · form4.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,940 Underlying: Common Stock · 42,940 shares Expires 2027-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a one-year performance condition tied to company-wide milestone performance for 2017, which was determined on February 21, 2018. Number of stock options reported represents the number of options earned based on milestone performance. F3 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2018, 2019 and 2020. Read SEC document |
| March 15, 2017 Filed Mar 15, 2017 22:12 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 63,000 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-17-011819 · form4.xml · derivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2027-03-15 F1 · derivative.exercise_date: These stock options vest in one-third increments on each of March 15, 2018, 2019 and 2020. Read SEC document |
| March 15, 2017 Filed Mar 16, 2020 20:38 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 69,750 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-20-010805 · form4.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,750 Underlying: Common Stock · 69,750 shares Expires 2027-03-15 F3 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a three-year performance condition tied to average cash profits during 2017-2019, which was determined on February 26, 2020. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
| March 15, 2017 Filed Mar 16, 2020 20:38 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 26,250 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001127602-20-010805 · form4.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2027-03-15 F2 · security: These performance-based stock options were initially awarded on March 15, 2017, subject to a three-year performance condition tied to average cash profits during 2017-2019, which was determined on February 26, 2020. Number of stock options reported represents the number of options earned based on performance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.